David Cosgrove

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein et al. · Annals of Oncology · 2020 · 1.4K citations · Full text

Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma

Timothy M. Pawlik, Diane K. Reyes, David Cosgrove et al. · Journal of Clinical Oncology · 2011 · 305 citations · Full text

Sorafenib Combined, Multimodality, Metronomic Therapy +16

Pattern of distant metastases in colorectal cancer: a SEER based study

Miao‐Zhen Qiu, Jianming Hu, Dajun Yang et al. · Oncotarget · 2015 · 248 citations · Full text

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

Edward A. Sausville, Patricia LoRusso, Michael A. Carducci et al. · Cancer Chemotherapy and Pharmacology · 2014 · 195 citations · Full text

Checkpoint Kinase Inhibitor, Medicine, Pathology +7